Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis, Inc. (NASDAQ: CRIS) has announced that CEO James Dentzer will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting January 11, 2021, at 6:00 am ET. A live webcast can be accessed on the company's website under "Events & Presentations". Curis focuses on developing cancer therapeutics, with current collaborations on innovative treatments including CA-4948 and CI-8993, both in clinical trials. For more details, visit www.curis.com.
Curis, Inc. (NASDAQ: CRIS) has concluded its public offering of 29.5 million shares at $5.75 each, raising approximately $159.1 million in net proceeds. The offering included an option for underwriters to purchase an additional 3.8 million shares. Funds will be used to advance the development of cancer therapeutics CA-4948 and CI-8993, and to support general working capital until 2023. The offering was executed under a previously filed registration statement with the SEC.
Curis, Inc. (NASDAQ:CRIS) announced the pricing of a public offering of 25,652,174 shares at $5.75 per share, totaling approximately $147.5 million in gross proceeds. The offering is expected to close around December 11, 2020, pending customary conditions. Proceeds will be used for the development of CA-4948 and CI-8893, along with general working capital. The offering is made under a shelf registration statement and involves underwriters such as Cantor Fitzgerald & Co. and JonesTrading Institutional Services.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced a proposed public offering of its common stock under an existing shelf registration statement. The company plans to grant underwriters a 30-day option to purchase additional shares, up to 15% of the offering size. Proceeds will fund the development of CA-4948 and CI-8993, while also supporting general working capital. Cantor Fitzgerald & Co. and JonesTrading are the joint lead book runners for this offering.
Curis (NASDAQ: CRIS) announced promising preliminary results from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor targeting acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Key findings include marrow blast reductions in all evaluable patients, with no dose-limiting toxicities reported. Out of 7 patients, 6 remain in the study. The results highlight CA-4948's potential, especially for patients who are relapsed or refractory. The company plans to provide further updates on the study in mid-2021.
Curis (NASDAQ: CRIS) announced updated data from its Phase 1 study of CA-4948, an IRAK4 kinase inhibitor for relapsed or refractory non-Hodgkin's lymphoma (NHL). Results indicate that the recommended Phase 2 dose of 300 mg BID demonstrates significant anti-cancer activity with a median tumor reduction of 27% in evaluable patients. The drug is well-tolerated, and preliminary data from biomarkers suggest potential for patient enrichment. A virtual presentation of these findings will occur at the 62nd American Society of Hematology Annual Meeting.
Curis, Inc. (NASDAQ: CRIS) announced a virtual KOL event on December 8, 2020, to discuss the IRAK4 kinase inhibitor CA-4948. This event will share progress from the Phase 1 study in patients with non-Hodgkin lymphoma and new clinical data for acute myeloid leukemia and myelodysplastic syndromes. The presentation will be led by James Dentzer, CEO, alongside Dr. Amit Verma. A live webcast will be available, with a replay accessible for 90 days after the event.
Curis, Inc. (NASDAQ: CRIS) reported its third-quarter 2020 financial results with a net loss of $6.0 million ($0.11 per share), an improvement from a loss of $6.4 million in Q3 2019. Total revenues were $2.7 million, slightly down from $2.9 million a year prior. Key operational highlights include ongoing Phase 1 studies for the IRAK4 inhibitor CA-4948 and the anti-VISTA antibody CI-8993. The company also secured a CRADA with NCI for CA-4948’s development and maintains a cash position of $23.6 million, sufficient for operations through mid-2021.
Curis, a biotechnology company (NASDAQ: CRIS), has entered a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop CA-4948, an IRAK4 kinase inhibitor for cancer treatment. This collaboration aims to enhance CA-4948's clinical studies and validate Curis's approach to targeted cancer therapeutics. CA-4948 is currently in Phase 1 trials for non-Hodgkin lymphoma and acute myeloid leukemia. The company also plans a combination study with ibrutinib, expected to start in Q4 2020.
Curis, Inc. (NASDAQ: CRIS) announced the acceptance of three abstracts for CA-4948 presentations at the 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. CA-4948 is a first-in-class IRAK4 inhibitor aimed at treating various hematologic malignancies. Data from Phase 1 studies in non-Hodgkin's lymphoma and acute myeloid leukemia are expected by year-end. The company emphasizes progress and will share updated safety and efficacy results during the conference.